MDGL
Madrigal Pharmaceuticals, Inc. · Healthcare · Biotechnology
动量输入（同类管理人）：
持有人广度 +12.5% ·
股份流向 -1.5% ·
净新建仓位 +11.1%
· 公式
持有人分散化：持有人数增多，合计持仓比例缩小。
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q3 2024
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 28.27K | $13.62M | n/a | n/a |
| Q2 2026 | 123 | +1 | 10.48M | $5.62B | +9 | −7 |
| Q1 2026 | 124 | +7 | 12.07M | $6.32B | +9 | −3 |
| Q4 2025 | 116 | 0 | 12.47M | $7.26B | +1 | n/a |
| Q3 2025 | 19 | +1 | 6.80M | $3.12B | +1 | −1 |
| Q2 2025 | 16 | 0 | 6.45M | $1.95B | n/a | n/a |
| Q1 2025 | 13 | +1 | 2.28M | $753.61M | +1 | n/a |
| Q4 2024 | 12 | +2 | 2.15M | $662.73M | +2 | n/a |
| Q3 2024 | 9 | +1 | 1.41M | $299.66M | +3 | −2 |
| Q2 2024 | 8 | n/a | 1.43M | $401.79M | n/a | n/a |
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 733.70K | -14.6% | $155.71M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 2 | Geode Capital Management ✦ (被动) | 405.65K | +1.4% | $86.10M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 3 | Marshall Wace ✦ | 80.40K | +4629.5% | $17.06M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | Norges Bank ✦ (被动) | 69.97K | -39.7% | $14.85M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 5 | Citadel Advisors ✦ | 54.65K | +388.4% | $11.60M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 6 | Renaissance Technologies ✦ | 44.50K | 新增 | $9.44M | 0.0% | New | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 9.03K | 新增 | $1.92M | 0.0% | New | 1 | SEC ↗ ×4 |
| 8 | Millennium Management ✦ | 8.93K | 新增 | $1.90M | 0.0% | New | 1 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 5.12K | +11.0% | $1.09M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例，即持仓信心指标。✦ = 精选管理人。
新增买入方
| Renaissance Technologies | $9.44M | 0.0% |
| Wellington Management | $1.92M | 0.0% |
| Millennium Management | $1.90M | 0.0% |
已清仓
| Point72 Asset Management | $11.47M | 曾为 0.0% |
| D. E. Shaw & Co. | $265,312 | 曾为 0.0% |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 374 持有人, 23.71M 股份, $12.08B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
持有该证券的受追踪机构最常同时持有的其他证券：基于共同持有计数，而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Officer, Director · 120 股 · $65,565
Officer, Director · 60 股 · $31,985
Officer, Director · 106 股 · $56,611
Officer, Director · 218 股 · $116,836
Officer, Director · 160 股 · $86,019
Officer, Director · 687 股 · $371,382
Officer, Director · 368 股 · $199,324
Officer, Director · 1.20K 股 · $652,209
Officer, Director · 1.54K 股 · $837,253
Officer, Director · 761 股 · $414,616
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论